4.0 Article

Malin restoration as proof of concept for gene therapy for Lafora disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Neurosciences

Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora

Pasquale Pellegrini et al.

Summary: Lafora disease (LD) is a fatal childhood-onset dementia characterized by the accumulation of glycogen aggregates in various organs, particularly in the brain. The presence of p62, an autophagy adaptor, plays a role in the formation of these aggregates, suggesting a protective mechanism to mitigate the harmful consequences of glycogen accumulation in the brain.

MOLECULAR NEUROBIOLOGY (2022)

Article Neurosciences

Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model

Belen Molla et al.

Summary: Lafora disease is a fatal rare neurodegenerative disorder characterized by epileptic seizures and polyglucosan inclusions in the brain. It is caused by mutations in two genes and currently lacks appropriate treatment. Neuroinflammation has been identified as a key factor, and anti-inflammatory treatments such as propranolol and EGCG have shown potential therapeutic effects in preclinical studies.

MOLECULAR NEUROBIOLOGY (2021)

Article Neurosciences

Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity

Olga Varea et al.

Summary: Lafora disease (LD) is a fatal adolescence-onset neurodegenerative condition characterized by the accumulation of aberrant glycogen aggregates known as Lafora bodies (LBs). Early suppression of glycogen synthase (MGS) can prevent LB formation and pathological manifestations of LD, but it is unclear whether late suppression of MGS can halt LB accumulation. Further research is needed to understand the potential therapeutic effects of targeting MGS in LD treatment.

NEUROBIOLOGY OF DISEASE (2021)

Article Clinical Neurology

Astrocytic glycogen accumulation drives the pathophysiology of neurodegeneration in Lafora disease

Jordi Duran et al.

Summary: Recent studies have shown that Lafora bodies are also present in astrocytes, not only in neurons. Blocking glycogen synthesis in astrocytes prevents the increase in neurodegeneration markers, autophagy impairment, and metabolic changes characteristic of the malin(KO) model.
Article Clinical Neurology

Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models

Emrah Gumusgoz et al.

Summary: Many adult and most childhood neurological diseases have a genetic basis, and CRISPR/Cas9 technology shows promise in treating them. By using CRISPR/Cas9 to disrupt gene sequences in adult polyglucosan body disease and Lafora disease mouse models, the researchers were able to reduce abnormal glycogen accumulation and improve neuroinflammatory markers, demonstrating the potential of this therapy for neurological diseases.

NEUROTHERAPEUTICS (2021)

Article Biochemistry & Molecular Biology

An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice

Silvia Nitschke et al.

Summary: The study demonstrates that knocking out Gys1 gene in LD mice can partially halt the progression of the disease but cannot fully reverse neurodegeneration and fatal epilepsy. While Gys1 knockout inhibits glycogen and Lafora body accumulation in skeletal muscle, it has some effect in preventing disease development in the brain. Additional research is needed to explore further mechanisms as glycogen and LBs still accumulate in certain tissues.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Review Neurosciences

Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock

Raygene Martier et al.

FRONTIERS IN NEUROSCIENCE (2020)

Article Cell Biology

Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion

M. Kathryn Brewer et al.

CELL METABOLISM (2019)

Review Pharmacology & Pharmacy

Gene Therapy Tools for Brain Diseases

Selene Ingusci et al.

FRONTIERS IN PHARMACOLOGY (2019)

Review Clinical Neurology

Lafora disease - from pathogenesis to treatment strategies

Felix Nitschke et al.

NATURE REVIEWS NEUROLOGY (2018)

Article Clinical Neurology

Lafora Disease: A Review of Molecular Mechanisms and Pathology

Brandy Verhalen et al.

NEUROPEDIATRICS (2018)

Article Multidisciplinary Sciences

QuPath: Open source software for digital pathology image analysis

Peter Bankhead et al.

SCIENTIFIC REPORTS (2017)

Article Clinical Neurology

PTG protein depletion rescues malin-deficient Lafora disease in mouse

Julie Turnbull et al.

ANNALS OF NEUROLOGY (2014)

Article Biochemistry & Molecular Biology

Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease

Jordi Duran et al.

HUMAN MOLECULAR GENETICS (2014)

Article Endocrinology & Metabolism

Neurons have an active glycogen metabolism that contributes to tolerance to hypoxia

Isabel Saez et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2014)

Article Medicine, Research & Experimental

Deleterious effects of neuronal accumulation of glycogen in flies and mice

Jordi Duran et al.

EMBO MOLECULAR MEDICINE (2012)

Article Medicine, Research & Experimental

Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease

Jordi Valles-Ortega et al.

EMBO MOLECULAR MEDICINE (2011)

Editorial Material Clinical Neurology

LAFORA BODIES IN SKELETAL MUSCLE ARE FIBER TYPE SPECIFIC

J. Turnbull et al.

NEUROLOGY (2011)

Article Genetics & Heredity

PTG Depletion Removes Lafora Bodies and Rescues the Fatal Epilepsy of Lafora Disease

Julie Turnbull et al.

PLOS GENETICS (2011)

Article Biochemistry & Molecular Biology

Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy

H Lohi et al.

HUMAN MOLECULAR GENETICS (2005)

Article Multidisciplinary Sciences

Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin

MS Gentry et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Article Biochemistry & Molecular Biology

The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies

S Ganesh et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)

Article Biochemistry & Molecular Biology

A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen

JY Wang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)

Review Clinical Neurology

Lafora's disease: Towards a clinical, pathologic, and molecular synthesis

BA Minassian

PEDIATRIC NEUROLOGY (2001)